Significant Customers and Concentrations of Risk - Summary of Significant Customers Comprising 10% or More of Total Revenue (Detail) - USD ($)		3 Months Ended
		Mar. 31, 2016	Mar. 31, 2015
Concentration Risk [Line Items]
Total revenues		$ 12,318,772	$ 8,348,037
Teva [Member]
Concentration Risk [Line Items]
Total revenues		6,485,850	2,332,815
McKesson [Member]
Concentration Risk [Line Items]
Total revenues	[1]	1,709,294	1,899,705
Ferring [Member]
Concentration Risk [Line Items]
Total revenues		1,658,622	1,471,416
LEO Pharma [Member]
Concentration Risk [Line Items]
Total revenues			857,143
AmerisourceBergen [Member]
Concentration Risk [Line Items]
Total revenues	[1]	$ 1,147,086	$ 875,145

[1] Represents estimated revenue based on OTREXUP™ shipments, a portion of which has not been recognized as revenue but is recorded in deferred revenue at the end of each period as discussed in Note 2 to the Consolidated Financial Statements.